Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study to Evaluate the Safety, Tolerability, and Efficacy of Intranasal Insulin and Glutathione as an Add-On Therapy in Subjects With Parkinson's Disease (NOSE-PD)
NCT05266417 is registered in ClinicalTrials.gov with Gateway Institute for Brain Research as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled, Phase II Study to Evaluate the Safety, Tolerability, and Efficacy of Intranasal Insulin and Glutathione as an Add-On Therapy in Subjects With Parkinson's Disease (NOSE-PD)
- Lead sponsor
- Gateway Institute for Brain Research
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- February 7, 2022
- Completion date
- November 30, 2027
- Enrollment
- 56 (estimated)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.